Get the Daily Brief
Latest Biotech News
GeneDx Reports 49% Revenue Growth Fueled by Genome and Exome Testing Expansion
GeneDx, a genetic diagnostics company, announced a 49% year-over-year revenue increase in Q2 2025, totaling $102.7 million and marking its fourth consecutive profitable quarter. Growth is...
AI-Powered ‘Virtual Labs’ Mimic Scientific Collaboration for Research Acceleration
Researchers from Stanford University and the Chan Zuckerberg Biohub developed a novel AI-based ‘Virtual Lab,’ where multiple specialized AI agents collaborate, simulating multidisciplinary...
CRISPR-GPT and AI Enhance Gene Editing Experiment Design
An interdisciplinary team from Stanford, Princeton, Google DeepMind, and UC Berkeley introduced CRISPR-GPT, an AI system combining large language models with expert knowledge to automate design...
Madrigal Pharmaceuticals Secures $2 Billion Deal for Preclinical GLP-1 Agonist
Madrigal Pharmaceuticals entered an exclusive global licensing agreement with China-based CSPC Pharmaceutical Group for SYH-2086, a preclinical oral small-molecule GLP-1 receptor agonist. The deal...
Expansion and Innovations in Cell and Gene Therapy Manufacturing at Academic Centers
Academic institutions like Roswell Park Comprehensive Cancer Center are significantly scaling in-house clinical-grade cell manufacturing facilities, enabling higher throughput and tighter...
FDA Shifts After Sarepta Gene Therapy Controversy
The FDA has reversed its earlier halt on Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy, allowing shipments to ambulatory patients to resume after investigations found...
Merck’s Strategic Cost-Cutting and Priorities Shift
Merck announced a $3 billion annual cost reduction plan by 2027 to redirect investments into newly launched and pipeline drugs across oncology and cardiometabolic areas ahead of upcoming...
Novo Nordisk’s Leadership and Financial Update in Obesity Market
Novo Nordisk appointed Mike Doustdar as its new CEO amid lowered financial guidance for 2025, cutting expected sales growth of blockbuster obesity and diabetes drugs Wegovy and Ozempic to 8–14%...
AI and Computational Tools Accelerate Biotech Research
Breakthroughs in AI-powered research environments and gene editing automation are transforming life sciences. The Virtual Lab platform utilizes AI agents specialized in scientific roles to conduct...
Advances and Challenges in Cell and Gene Therapy Manufacturing
Digitization in cell and gene therapy (CGT) manufacturing is increasing traceability and efficiency but also raising cybersecurity risks, highlighting the sector’s emerging critical infrastructure...
Biopharma Collaborations and Financings Shape Growth Trajectories
Strategic partnerships and capital raises marked the biopharma landscape, with Bristol Myers Squibb spinning off five autoimmune assets into a new company supported by $300 million from Bain...
Innovations in Diagnostic and Therapeutic Technologies
Novel diagnostic improvements and therapy candidates continue to surface. Apellis Pharmaceuticals gained FDA approval expanding Empaveli's use to two rare kidney diseases, complement 3...
Alzheimer’s and Neurodegeneration Research Advances
Multiple studies highlight progress in understanding and treating neurodegenerative diseases. New data suggest that amyloid-clearing Alzheimer’s drugs from Eli Lilly and Eisai have amplified...
Regulatory and Market Sentiment Shifts in Biotech
The biotech and healthcare sectors are navigating volatile regulatory and market environments. FDA leadership changed with Vinay Prasad's departure amid controversies. NeoGenomics faced stock...
FDA Clears Sarepta to Resume Gene Therapy Shipments for Duchenne Muscular Dystrophy – Ambulatory Patients Back on Track
After a week-long pause initiated due to safety concerns following patient fatalities, the U.S. Food and Drug Administration (FDA) has authorized Sarepta Therapeutics to resume shipments of its...
Novo Nordisk Downgrades 2025 Sales Outlook as Obesity Drug Faces Market Challenges – Leadership Transition Unfolds
Danish pharmaceutical leader Novo Nordisk has revised down its full-year 2025 sales growth forecast for its flagship GLP-1 products Wegovy and Ozempic to 8%–14%, from an earlier 13%–21%...
GeneDx Posts 49% Revenue Growth Fueled by Genome and Exome Testing Expansion
Genetic diagnostics company GeneDx reported strong second-quarter 2025 financial results with revenues reaching $102.7 million, up 49% year-over-year. The growth was driven by a substantial 69%...
Merck Initiates $3 Billion Cost-Cutting Effort to Finance New Product Launches – Portfolio Transformation Underway
Merck & Co. unveiled a major multiyear cost optimization initiative aimed at reducing annual expenses by $3 billion by the end of 2027. This strategy will redirect funds from mature assets toward...
GSK and Hengrui Ink $12.5 Billion Deal Targeting COPD and Oncology Pipeline Expansion
GlaxoSmithKline plc (GSK) and China-based Hengrui Pharmaceuticals Co. Ltd. entered into a strategic collaboration valued at up to $12.5 billion to develop and commercialize up to 12 drug...
Apellis Pharmaceuticals’ Empaveli Gains FDA Approval for Rare Kidney Disorders – Expands Market Potential
Apellis Pharmaceuticals and Sobi secured FDA approval for pegcetacoplan (Empaveli) to treat complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis...